Next-Generation Wireless Device May Enable Telehealth And Remote Patient Monitoring in the Future EMERYVILLE, Calif., [January 28, 2020] – Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced ...

Awarded 2018 Entrepreneurial Company of the Year for real-time body chemistry monitoring South San Francisco, Calif. – October 15, 2018 – Profusa, a company dedicated to the development of tissue-integrating biosensors for the continuous monitoring ...

Profusa Software and Systems Lead, Kevin Zhao, has been selected to participate in the Defense Advanced Research Projects Agency’s (DARPA) 60th Anniversary Symposium (D60) as a DARPA Riser. The D60 Symposium takes place from September ...

Leading global investors join this round; financing will accelerate commercialization of Lumee™ Oxygen Platform and pioneering glucose biosensors South San Francisco, Calif. – August 14, 2018 – Profusa, a company dedicated to the development of ...

Novel microsensing technology that reflects microvascular perfusion and oxygen supply in tissue shows promise in patients with chronic limb-threatening ischemia.

NEW ORLEANS, March 19, 2018 — Up until now, local inflammation and scar tissue from the so-called “foreign body response” has prevented ...

We are becoming more accustomed to continually tracking health metrics with smart wearable devices. The next step will be implantable devices, which provide real-time monitoring of body chemistry. That future is already here and will ...

Leading Healthcare Authority and Public Health Advocate to Advise Developer of Tissue-integrated Sensors for Real-time Monitoring of Body Chemistry SOUTH SAN FRANCISCO, Calif., June 7, 2017 — Profusa, Inc. announced today that William Frist, M.D., ...